Network’s investment strategy focuses on companies developing novel therapies for age-related conditions and biological rejuvenation.
Reflecting the significant investor rebound observed in our 2024 Annual Longevity Investment Report, the Longevity Investor Network has also reported positive results in 2024, with a significant expansion in both its investor base and financial contributions to the rejuvenation biotech sector. Over the course of last year, the network, an initiative of the Lifespan Research Institute, saw its membership double, reflecting the growing investor enthusiasm for scientific approaches to addressing the root causes of aging.
The surge in LIN’s engagement was matched by increased capital deployment, with over $650,000 invested in early-stage longevity-focused biotech firms, bringing the total capital invested by the network since 2020 to more than $5.5 million. The network’s investment strategy is focused on companies developing novel therapies for age-related conditions and biological rejuvenation.
Among the supported ventures was XM Therapeutics, which is working on extracellular matrix-based platforms aimed at regenerating tissues and organs. BioIO received backing for its work on a compound that modulates sirtuin 3 to treat metabolic disorders. LEAH Labs attracted support for its development of CAR-T therapies designed for lymphoma in companion animals, with potential for future human applications. Vivian Therapeutics also joined the portfolio, recognized for its use of genetically engineered fruit fly models to identify personalized cancer treatment combinations through its proprietary Personal Discovery Process.
“We are living through a remarkable turning point in biomedical history,” said LIN managing director Javier Noris. “The longevity biotechnology industry, once considered speculative, is now entering a phase of real-world traction. We’re seeing a wave of therapies in clinical trials, from senolytics to cellular reprogramming, inch closer to public availability. The pipeline is no longer theoretical– it’s operational.”
Throughout 2024, the Longevity Investor Network intensified its efforts to build and educate a committed investor community. It hosted 25 investor pitch sessions that showcased over 70 longevity startups, alongside five educational seminars designed to deepen investor understanding of the rapidly evolving field. Since its inception, the network has supported 19 companies across diverse domains including neurodegeneration, tissue repair, immunotherapy, and metabolic health. This activity is part of a broader mission to catalyze the development of therapeutics capable of extending human healthspan and to drive a shift in how aging is approached from a medical standpoint.
Photograph: KanawatTH/Envato
The post Longevity Investor Network doubles in size in 2024 appeared first on Longevity.Technology – Latest News, Opinions, Analysis and Research.
